Which drug tames skin vasculitis best? new trial aims to find out
NCT ID NCT02939573
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests three standard medications—colchicine, dapsone, and azathioprine—in 90 people with isolated skin vasculitis (inflammation of small or medium blood vessels in the skin). Participants are randomly assigned to one of the drugs, and doctors track how well the skin responds over 12 months. The goal is to see which drug works best to control the condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
colchicine, dapsone, or azathioprine
What this could lead to
If successful, this trial could identify which of these three existing drugs works best for controlling skin vasculitis, helping doctors choose the most effective treatment.
What could go wrong
This is a phase 2 trial with only 90 participants, so results may not apply to everyone. The drugs have known side effects, and the study may not find a clear winner.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HENOCH-SCHÖNLEIN PURPURA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Boston University School of Medicine
COMPLETEDBoston, Massachusetts, 02118, United States
-
Cleveland Clinic
COMPLETEDCleveland, Ohio, United States
-
Hospital for Special Surgery
COMPLETEDNew York, New York, 10021, United States
-
Mayo Clinic
COMPLETEDRochester, Minnesota, 55905, United States
-
McGill University Health Centre
RECRUITINGMontreal, Quebec, H4A 3J1, Canada
Contact Email: •••••@•••••
-
Northwell Health
COMPLETEDLake Success, New York, 11042, United States
-
Penn State Hershey Medical Center
COMPLETEDHershey, Pennsylvania, 17033, United States
-
St. Joseph's Healthcare
RECRUITINGHamilton, Ontario, Canada
Contact Email: •••••@•••••
-
Tohoku Medical and Pharmaceutical University Hospital
COMPLETEDKyoto, 602-8566, Japan
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
-
University of Kansas Medical Center
RECRUITINGKansas City, Kansas, United States
Contact Email: •••••@•••••
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Email: •••••@•••••
-
University of Toronto Mount Sinai Hospital
RECRUITINGToronto, Ontario, Canada
Contact Email: •••••@•••••
-
University of Utah
COMPLETEDSalt Lake City, Utah, United States
-
University of Virginia
RECRUITINGCharlottesville, Virginia, 22903, United States
Contact Email: •••••@•••••
-
Vanderbilt University
RECRUITINGNashville, Tennessee, 37232, United States
Contact Email: •••••@•••••